Kiniksa Pharmaceuticals Intern - COM (KNSA)

CUSIP: G5269C101

Q3 2020 13F Holders as of 30 Sep 2020

Type / Class
Equity / COM
Total 13F shares
28,297,751
Share change
+7,530,146
Total reported value
$433,552,379
Put/Call ratio
82%
Price per share
$15.32
Number of holders
100
Value change
+$112,164,880
Number of buys
76
Number of sells
26

Quarterly Holders Quick Answers

What is CUSIP G5269C101?
CUSIP G5269C101 identifies KNSA - Kiniksa Pharmaceuticals Intern - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q3 2020

As of 30 Sep 2020, Kiniksa Pharmaceuticals Intern - COM (KNSA) was held by 100 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 28,297,751 shares. The largest 10 holders included HILLHOUSE CAPITAL ADVISORS, LTD., BAKER BROS. ADVISORS LP, Consonance Capital Management LP, VANGUARD GROUP INC, AMERIPRISE FINANCIAL INC, BlackRock Inc., ArrowMark Colorado Holdings LLC, Vivo Capital, LLC, JANUS HENDERSON GROUP PLC, and CITADEL ADVISORS LLC. This page lists 100 institutional shareholders reporting positions in this security for the Q3 2020 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.